Abstract library

156 results for "biliary tract".
#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract
Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo
Authors:
#1477 Neuroendocrine Tumors of the Biliary Tract: A Retrospective, Observational Multicenter Study
Introduction: Neuroendocrine tumors of the biliary tract (BTNETs) constitute a heterogeneous group of neoplasms. Because of their rarity, the clinical behavior is unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Maria Pia Brizzi
Authors:
#2111 Biliary Neuroendocrine Tumors: A Retrospective Analysis of 28 Patients Since 1991
Introduction: Biliary neuroendocrine tumors represent less than 1% of all neuroendocrine tumors (NETs), and the related clinical study is limited.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Zhibo Zheng
Authors:
#608 Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)?
Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors:
Keywords: NEC, octreotide, GEP, HB
#1724 Outcomes of Hepatobiliary Neuroendocrine Neoplasms Treated with Systemic Therapy: A Retrospective Analysis.
Introduction: Primary hepatobiliary neuroendocrine neoplasms (NEN) are rare. Knowledge about clinicopathological findings and treatment results of hepatobiliary NEN is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Komiyama Satoshi
Authors:
#991 Primary Neuroendocrine Tumor of Extrahepatic Bile Duct
Introduction: Biliary tract primary malignant tumors are rare neoplasms. Eighty-five per cent are cholangiocarcinomas, being in exceptional cases a neuroendocrine tumor. The absence of clinical suspiction involves a difficult preoperative diagnosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Jose Angel Flores Garcia
Authors:
#2117 Neuroendocrine Tumors: An Australian Experience
Introduction: Neuroendocrine tumours (NETs) in Australia are rare, but are rising in incidence.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Vivek Ashoka Menon
Authors:
#2222 Biliary Mixed Neuroendocrine-Nonneuroendocrine Neoplasms: A Series of Four Cases with Review of Literature
Introduction: Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs) are rare tumors comprising of both adenocarcinoma and neuroendocrine component, at least 30% of each in the lesion.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Prasad Pande
Authors:
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
Authors:
#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System
Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: MD Tomohiro Yamaguchi
Authors: